Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Maxim YankelevichArchana ThakurShakeel ModakRoland ChuJeffrey TaubAlissa MartinDana SchalkAmy SchienshangSarah WhitakerKatie ReaDaniel W LeeQin LiuAnthony F ShieldsNai Kong V CheungLawrence G LumPublished in: Journal for immunotherapy of cancer (2024)
cells/kg/infusion. Coupled with evidence of post-treatment endogenous immune responses, our findings support further investigation of GD2BATs in larger phase II clinical trials.
Keyphrases
- phase ii
- clinical trial
- open label
- immune response
- induced apoptosis
- cell cycle arrest
- phase iii
- double blind
- low dose
- toll like receptor
- cancer therapy
- placebo controlled
- dendritic cells
- cell death
- oxidative stress
- cell proliferation
- inflammatory response
- combination therapy
- smoking cessation
- pi k akt
- replacement therapy